R
Robert J. Mentz
Researcher at Duke University
Publications - 557
Citations - 13913
Robert J. Mentz is an academic researcher from Duke University. The author has contributed to research in topics: Heart failure & Medicine. The author has an hindex of 46, co-authored 429 publications receiving 9511 citations. Previous affiliations of Robert J. Mentz include Novant Health & Durham University.
Papers
More filters
Journal ArticleDOI
Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.
Rury R. Holman,M. Angelyn Bethel,Robert J. Mentz,Vivian P. Thompson,Yuliya Lokhnygina,John B. Buse,Juliana C.N. Chan,Jasmine Choi,Stephanie M. Gustavson,Nayyar Iqbal,Aldo P. Maggioni,Steven P. Marso,Peter Öhman,Neha J. Pagidipati,Neil Poulter,Ambady Ramachandran,Bernard Zinman,Adrian F. Hernandez +17 more
TL;DR: Among patients with type 2 diabetes with or without previous cardiovascular disease, the incidence of major adverse cardiovascular events did not differ significantly between patients who received exenatide and those who received placebo.
Journal ArticleDOI
Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis.
M. Angelyn Bethel,Rishi A Patel,Peter Merrill,Yuliya Lokhnygina,John B. Buse,Robert J. Mentz,Neha J. Pagidipati,Juliana C.N. Chan,Stephanie M. Gustavson,Nayyar Iqbal,Aldo P. Maggioni,Peter Öhman,Neil Poulter,Ambady Ramachandran,Bernard Zinman,Bernard Zinman,Adrian F. Hernandez,Rury R. Holman +17 more
TL;DR: Overall cardiovascular safety across all GLP-1 receptor agonist cardiovascular outcome trials is shown and drugs in this class can reduce three-point major adverse cardiovascular events, cardiovascular mortality, and all-cause mortality risk, albeit to varying degrees for individual drugs, without significant safety concerns.
Journal ArticleDOI
Noncardiac Comorbidities in Heart Failure With Reduced Versus Preserved Ejection Fraction
Robert J. Mentz,Jacob P. Kelly,Thomas G. von Lueder,Adriaan A. Voors,Carolyn S.P. Lam,Martin R. Cowie,Keld Kjeldsen,Ewa A. Jankowska,Dan Atar,Javed Butler,Mona Fiuzat,Faiez Zannad,Bertram Pitt,Christopher M. O'Connor +13 more
TL;DR: The role of noncardiac comorbidities in patients with HFpEF versus HFrEF is summarized, emphasizing prevalence, underlying pathophysiologic mechanisms, and outcomes, and implications for clinical care and future HF clinical trial design.
Journal ArticleDOI
Palliative Care in Heart Failure: The PAL-HF Randomized, Controlled Clinical Trial
Joseph G. Rogers,Chetan B. Patel,Robert J. Mentz,Bradi B. Granger,Karen E. Steinhauser,Mona Fiuzat,Patricia A. Adams,Adam Speck,Kimberly S. Johnson,Arun Krishnamoorthy,Hongqiu Yang,Kevin J. Anstrom,Gwen C. Dodson,Donald H. Taylor,Jerry Kirchner,Daniel B. Mark,Christopher M. O’Connor,James A. Tulsky +17 more
TL;DR: An interdisciplinary palliative care intervention in advanced HF patients showed consistently greater benefits in quality of life, anxiety, depression, and spiritual well-being compared with UC alone.
Journal ArticleDOI
Type 2 Diabetes Mellitus and Heart Failure: A Scientific Statement From the American Heart Association and the Heart Failure Society of America: This statement does not represent an update of the 2017 ACC/AHA/HFSA heart failure guideline update
Shannon M. Dunlay,Michael M. Givertz,David Aguilar,Larry A. Allen,Michael Chan,Akshay S. Desai,Anita Deswal,Victoria Vaughan Dickson,Mikhail Kosiborod,Carolyn L. Lekavich,Rozalina G. McCoy,Robert J. Mentz,Ileana L. Piña +12 more
TL;DR: The approach to pharmacological therapy and lifestyle modification in patients with diabetes mellitus and heart failure is reviewed; the value of multidisciplinary interventions to improve clinical outcomes in this population is highlighted; and priorities for future research are outlined.